Anzeige
Mehr »
Login
Mittwoch, 15.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Löst diese riesige Entdeckung die Kupferkrise der KI? So ändert sich die Rechnung durch diesen Explorer!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QA04 | ISIN: IL0011794802 | Ticker-Symbol:
NASDAQ
14.01.25
22:00 Uhr
22,280 US-Dollar
0,000
0,00 %
1-Jahres-Chart
CELLEBRITE DI LTD Chart 1 Jahr
5-Tage-Chart
CELLEBRITE DI LTD 5-Tage-Chart
GlobeNewswire (Europe)
354 Leser
Artikel bewerten:
(2)

Cellebrite DI Ltd: Cellebrite Appoints Tech Veteran Troy K. Richardson to Board of Directors

Finanznachrichten News

Seasoned Executive Brings Significant Operational and Sales Experience from Leading Technology Companies as Cellebrite Further Expands its Business Globally

TYSONS CORNER, Va. and PETAH TIKVA, Israel, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Cellebrite (NASDAQ: CLBT), a global leader in premier digital investigative solutions for the public and private sectors, announced today that Troy Richardson has joined its board of directors, effective August 13, 2024.

Mr. Richardson is a seasoned technology executive with more than 30 years of experience in leading, scaling and transforming global organizations. He currently serves on the Unisys Corporation (NYSE: UIS) Board of Directors and previously served as a Director of the Board for Carestream Dental. Mr. Richardson was president of the Digital Thread group at PTC Inc. (NASDAQ: PTC) from 2021 until 2022 after having served as executive vice president and chief operating officer from 2020 to 2021. Mr. Richardson's three decades of senior leadership roles span some of the largest and most successful global technology companies including DXC (formerly Computer Sciences Corporation prior to its merger with HP Enterprise), Oracle, SAP, Hewlett-Packard Novell, and IBM. With the appointment of Troy Richardson, Cellebrite's Board of Directors now consists of 10 directors. Mr. Richardson is based in metropolitan Atlanta.

"We are delighted to welcome Troy to our board of directors," said Thomas Hogan, Executive Chairman of the Board of Cellebrite. "Troy is an outstanding leader who brings a wealth of expertise and insight to our Company. His deep knowledge of the software industry, combined with his broad leadership experience spanning sales, marketing, corporate development and customer success, will be invaluable as we continue to execute our strategy and deliver outstanding value to our customers. We look forward to benefiting from Troy's counsel as we further scale our business, fortify and expand our market leadership, advance innovation and drive shareholder value."

"I am honored and excited to join Cellebrite's board of directors," said Richardson. "Cellebrite has established its leadership position in the digital investigative and intelligence gathering industry, with a strong culture of innovation, customer focus, and social responsibility. I look forward to collaborating with Tom and the rest of the Board, as well as with Cellebrite's talented management team and employees, to help Cellebrite achieve its full potential and continue making a positive, enduring impact on the world."

Mr. Richardson holds a bachelor's degree in business administration from Eastern Illinois University and a master's degree in business administration from Northwestern University's J.L. Kellogg School of Management. He was appointed to Unisys' Corporation's Board of Directors in 2021 and currently serves on the Board's Audit & Finance and Rick & Security Committees. Mr. Richardson also served on Carestream Dental Board of Directors from 2021 to 2024.

About Cellebrite

Cellebrite's (Nasdaq: CLBT) mission is to enable its customers to protect and save lives, accelerate justice and preserve privacy in communities around the world. We are a global leader in Digital Investigative solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Trusted by thousands of leading agencies and companies worldwide, Cellebrite's Digital Investigative platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. To learn more visit us at www.cellebrite.com, https://investors.cellebrite.com, or follow us on X at @Cellebrite.

Contacts:

Media
Victor Ryan Cooper
Sr. Director of Corporate Communications + Content Operations
Victor.cooper@cellebrite.com
+1 404.804.5910

Investors
Andrew Kramer
Vice President, Investor Relations
investors@cellebrite.com
+1 973.206.7760

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/947dd533-8273-47a0-9fdb-eac0d18d28c5


© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.